247 related articles for article (PubMed ID: 20163297)
21. Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: the ECRIT study.
Sieber J; Neis M; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Merk H
Expert Opin Drug Saf; 2012 Jan; 11(1):7-13. PubMed ID: 21980934
[TBL] [Abstract][Full Text] [Related]
22. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
[TBL] [Abstract][Full Text] [Related]
23. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
[TBL] [Abstract][Full Text] [Related]
24. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract.
Amar SM; Harbeck RJ; Sills M; Silveira LJ; O'Brien H; Nelson HS
J Allergy Clin Immunol; 2009 Jul; 124(1):150-156.e1-5. PubMed ID: 19523672
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
26. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
[TBL] [Abstract][Full Text] [Related]
27. Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents.
Seidenberg J; Pajno GB; Bauer CP; La Grutta S; Sieber J
J Investig Allergol Clin Immunol; 2009; 19(2):125-31. PubMed ID: 19476016
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study.
Vervloet D; Birnbaum J; Laurent P; Hugues B; Fardeau MF; Massabie-Bouchat YP; Aferiat-Derome A; André C
Int Arch Allergy Immunol; 2007; 142(3):239-46. PubMed ID: 17114889
[TBL] [Abstract][Full Text] [Related]
29. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care.
Röder E; Berger MY; Hop WC; Bernsen RM; de Groot H; Gerth van Wijk R
J Allergy Clin Immunol; 2007 Apr; 119(4):892-8. PubMed ID: 17321581
[TBL] [Abstract][Full Text] [Related]
30. Sublingual immunotherapy in the treatment of adult allergic rhinitis patients.
Canonica GW; Passalacqua G
Allergy; 2006; 61 Suppl 81():20-3. PubMed ID: 16792602
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
Worm M
Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
[TBL] [Abstract][Full Text] [Related]
32. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
Roberts G; Hurley C; Turcanu V; Lack G
J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
[TBL] [Abstract][Full Text] [Related]
33. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma.
Rossi RE; Monasterolo G
Int J Immunopathol Pharmacol; 2005; 18(2):277-85. PubMed ID: 15888250
[TBL] [Abstract][Full Text] [Related]
34. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy.
Pokladnikova J; Krcmova I; Vlcek J
Ann Allergy Asthma Immunol; 2008 May; 100(5):482-9. PubMed ID: 18517082
[TBL] [Abstract][Full Text] [Related]
35. The safety of sublingual immunotherapy with one or multiple pollen allergens in children.
Agostinis F; Foglia C; Landi M; Cottini M; Lombardi C; Canonica GW; Passalacqua G
Allergy; 2008 Dec; 63(12):1637-9. PubMed ID: 19032238
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
[TBL] [Abstract][Full Text] [Related]
37. Certainties and doubts about sublingual and oral immunotherapy in children.
Larenas-Linnemann D
Curr Opin Allergy Clin Immunol; 2009 Dec; 9(6):558-67. PubMed ID: 19812482
[TBL] [Abstract][Full Text] [Related]
38. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children.
Ibañez MD; Kaiser F; Knecht R; Armentia A; Schöpfer H; Tholstrup B; Bufe A
Pediatr Allergy Immunol; 2007 Sep; 18(6):516-22. PubMed ID: 17680910
[TBL] [Abstract][Full Text] [Related]
39. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
Kleine-Tebbe J; Ribel M; Herold DA
Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193
[TBL] [Abstract][Full Text] [Related]
40. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children.
Tripodi S; Di Rienzo Businco A; Benincori N; Scala G; Pingitore G
Int Arch Allergy Immunol; 2006; 139(2):149-52. PubMed ID: 16374025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]